GlassScriptPhysician profile
Rajen S Patel
NPI 1285861443
$1,372.11
in general payments reported to CMS, 2019-2025
20 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $28.06 · 2021: $57.52 · 2022: $13.13 · 2023: $293 · 2024: $325 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $401.44 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $217.48 | 2019-2025 | Spravato, Xarelto |
| Pfizer INC. | $133.27 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.10 | 2025 | Caplyta |
| Exact Sciences Corporation | $83.66 | 2025 | Cologuard Collection Kit |
| Shockwave Medical, INC | $79.57 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Axsome Therapeutics, INC. | $63.42 | 2025 | Auvelity |
| Mallinckrodt Enterprises LLC | $43.36 | 2019 | |
| Bausch Health US, LLC | $36.49 | 2024-2025 | Aplenzin, Wellbutrin |
| Corium, LLC | $25.21 | 2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $24.54 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $24.54 | 2024 | Nuplazid |
| Corcept Therapeutics | $24.11 | 2025 | Korlym |
| Noven Therapeutics, LLC | $23.78 | 2025 | Xelstrym |
| Phadia US INC. | $21.38 | 2024 | Immunocap |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.34 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $18.96 | 2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $16.45 | 2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $16.08 | 2025 | Jornay Pm |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajen Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.